FDA Peptide Reclassification 2026: What It Means for European Buyers

On February 27, 2026, Robert F. Kennedy Jr. (HHS Secretary) announced that 14 peptides previously placed on the FDA's Category 2 list would be moved back to Category 1. Category 2 substances are considered not eligible for compounding by 503A/503B pharmacies in the United States. The reclassification to Category 1 means these peptides can once again be legally compounded by licensed US pharmacies, subject to standard compounding regulations.

This decision reversed a controversial 2023–2024 FDA action that had effectively restricted access to several widely-used research peptides in the US market. The announcement was framed as part of broader 'health freedom' policy initiatives within the new administration.

The 14 peptides returned to Category 1 include:

• BPC-157 (Body Protection Compound-157)
• Thymosin Alpha-1
• Thymosin Beta-4 (TB-500)
• KPV (alpha-MSH fragment)
• GHK-Cu (Copper peptide)
• Epithalon (Epitalon)
• Selank
• Semax
• DSIP (Delta Sleep-Inducing Peptide)
• Dihexa
• SS-31 (Elamipretide)
• MOTS-c
• Humanin
• PE-22-28 (Spadin analogue)

Notably, GLP-1 receptor agonists (semaglutide, tirzepatide) were NOT part of this reclassification, as those remain under separate pharmaceutical patent and exclusivity frameworks.

A critical point often misunderstood: FDA decisions have zero direct legal authority in the European Union. The EU pharmaceutical market is governed by the European Medicines Agency (EMA) at the centralized level and by national competent authorities (e.g., BfArM in Germany, ANSM in France, EOF in Greece) at the member-state level.

The FDA's Category 1/2 classification system is specific to US compounding pharmacy law (the Federal Food, Drug, and Cosmetic Act, sections 503A and 503B). No equivalent 'category' system exists in EU regulation.

In practice, many of these 14 peptides have been continuously available in EU markets through research chemical suppliers, as they are not classified as controlled substances under EU or national drug scheduling frameworks. Their legal status in Europe depends on whether they are classified as:

• Medicinal products (requiring marketing authorization)
• Research chemicals (available for laboratory use)
• Active pharmaceutical ingredients (regulated under GMP frameworks)

The regulatory landscape for peptides in Europe is complex and varies by member state. In general:

Research chemicals: Most of the 14 peptides listed above can be legally purchased as 'research chemicals' or 'reference standards' for laboratory, in vitro, or educational use in many EU jurisdictions. This is the framework under which the majority of European peptide suppliers operate.

Prescription peptides: Some peptides like Thymosin Alpha-1 (marketed as Zadaxin® in some countries) have or have had marketing authorization in specific jurisdictions. Semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) are fully EMA-approved medicines.

Gray areas: The line between 'research chemical' and 'unapproved medicinal product' can be ambiguous. EU authorities have increasingly scrutinized peptide suppliers, particularly those implicitly marketing products for human use without authorization.

Important: This article is educational and does not constitute legal advice. Always verify the specific regulations in your country of residence.

Several developments may affect European peptide access in 2026–2027:

• EMA Novel Food Regulation: The European Commission is evaluating whether certain bioactive peptides should be reclassified under the Novel Foods framework (Regulation EU 2015/2283), which would affect oral peptide products.

• UK MHRA Post-Brexit Policy: The UK's Medicines and Healthcare products Regulatory Agency operates independently from the EMA and may adopt different approaches to peptide classification.

• EU Pharmaceutical Legislation Reform: The ongoing revision of EU pharmaceutical legislation (proposed 2023, expected adoption 2026–2027) could introduce new frameworks relevant to peptide-based therapies.

• Compounding Pharmacy Harmonization: Several EU member states are updating their national compounding pharmacy regulations, which could create new legal pathways for peptide access — or restrict existing ones.

• Quality and Safety Standards: Regardless of legal status, the EU's increasing focus on GMP (Good Manufacturing Practice) standards for research chemicals may affect which suppliers can operate in the European market.

The FDA's reclassification is symbolically significant — it signals a potential shift toward greater regulatory acceptance of peptide-based therapies globally. However, European buyers should focus on EMA and national regulatory developments rather than FDA decisions when evaluating access and legality.